These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Parker WAE; Schulte C; Barwari T; Phoenix F; Pearson SM; Mayr M; Grant PJ; Storey RF; Ajjan RA Cardiovasc Diabetol; 2020 Jan; 19(1):3. PubMed ID: 31910903 [TBL] [Abstract][Full Text] [Related]
3. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. Gager GM; Jilma B; Winter MP; Hengstenberg C; Lang IM; Toma A; Prüller F; Wallner M; Kolesnik E; von Lewinski D; Siller-Matula JM Eur J Clin Invest; 2020 Nov; 50(11):e13304. PubMed ID: 32506444 [TBL] [Abstract][Full Text] [Related]
4. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G; Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855 [TBL] [Abstract][Full Text] [Related]
6. Antiplatelet therapy in cardiovascular disease: Current status and future directions. Passacquale G; Sharma P; Perera D; Ferro A Br J Clin Pharmacol; 2022 Jun; 88(6):2686-2699. PubMed ID: 35001413 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y Franchi F; Rollini F; Faz G; Rivas JR; Rivas A; Agarwal M; Briceno M; Wali M; Nawaz A; Silva G; Shaikh Z; Maaliki N; Fahmi K; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Baber U; Mehran R; Jennings LK; Bass TA; Angiolillo DJ J Am Heart Assoc; 2020 Apr; 9(8):e015865. PubMed ID: 32306797 [TBL] [Abstract][Full Text] [Related]
8. Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease. Galli M; Rollini F; Been L; Zenni MM; Angiolillo DJ; Franchi F J Thromb Thrombolysis; 2022 Oct; 54(3):461-469. PubMed ID: 36048358 [TBL] [Abstract][Full Text] [Related]
9. Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy? Van de Werf F Circulation; 2017 May; 135(18):1675-1676. PubMed ID: 28461411 [No Abstract] [Full Text] [Related]
10. Efficacy and Safety of High Potent P2Y Schreuder MM; Badal R; Boersma E; Kavousi M; Roos-Hesselink J; Versmissen J; Visser LE; Roeters van Lennep JE J Am Heart Assoc; 2020 Feb; 9(4):e014457. PubMed ID: 32063118 [TBL] [Abstract][Full Text] [Related]
12. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population. Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483 [TBL] [Abstract][Full Text] [Related]
13. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database. Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197 [TBL] [Abstract][Full Text] [Related]
14. Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. Sun MT; Huang S; Wiviott SD; Antman EM; Roe MT; Ohman EM; Neely M; Wallentin L; Wong CX Am J Cardiol; 2020 Apr; 125(8):1280-1283. PubMed ID: 32081368 [TBL] [Abstract][Full Text] [Related]
15. Update on Dual Antiplatelet Therapy for Secondary Stroke Prevention. Stringberg A; Camden R; Qualls K; Naqvi SH Mo Med; 2019; 116(4):303-307. PubMed ID: 31527979 [TBL] [Abstract][Full Text] [Related]
16. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors. Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954 [TBL] [Abstract][Full Text] [Related]
17. Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry). Khalid U; Bandeali S; Jones PG; Virani SS; Hira R; Hamzeh I; Chan PS; Kleiman NS; Lakkis N; Alam M Am J Cardiol; 2019 Dec; 124(12):1807-1812. PubMed ID: 31668345 [TBL] [Abstract][Full Text] [Related]
18. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850 [TBL] [Abstract][Full Text] [Related]
19. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors. Coccheri S Drugs; 2010 May; 70(7):887-908. PubMed ID: 20426498 [TBL] [Abstract][Full Text] [Related]